This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heijn, M. Articles by Jain, R. K. Search for Related Content PubMed PubMed Citation Articles by Heijn, M. Articles by Jain, R. K.

Cellular Membrane Permeability of Anthracyclines Does Not Correlate with Their Delivery in a Tissue-isolated Tumor¹

Department of Radiation Oncology, Edwin L. Steele Laboratory, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114

The clearance of anthracyclines from the vasculature was studied in perfused tissue-isolated tumors. Human tumor lines MCF-7, U87, and LS174T were implanted in the ovarian fat pad of immune-deficient mice and grown isolated from the surrounding tissue. The initial and continuous tissue uptakes of doxorubicin, daunorubicin, and idarubicin were measured. The clearance of these anthracyclines from the perfused vasculature of the tissue-isolated tumor was calculated using BSA as an intravascular marker. The measured clearances ranged from 50–200 µl/min/g tumor tissue, and the fractional clearances were between 0.30 and 0.70. On the basis of the in vitro cellular uptake rates of the anthracyclines, we expected a higher clearance of idarubicin than of doxorubicin. No significant differences were found among the clearances of the anthracyclines or among the tumor lines. The observed similarities in clearance of the anthracyclines was largely explained by differences in their protein binding and tissue diffusion gradients.

This article has been cited by other articles:

				R. J. Veldman, G. A. Koning, A. van Hell, S. Zerp, S. R. Vink, G. Storm, M. Verheij, and W. J. van Blitterswijk Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 704 - 710. [Abstract] [Full Text] [PDF]

				R. E. Eliaz, S. Nir, C. Marty, and F. C. Szoka Jr. Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes Cancer Res., January 15, 2004; 64(2): 711 - 718. [Abstract] [Full Text] [PDF]